No. RFA-DK-27-121 · National Institutes of Health
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
- Award range
- Up to $1,000,000
- Expected awards
- ~3
- Application deadline
- Oct 9, 2026
- Posted
- Jun 8, 2026
- Last verified
- Yesterday
At a glance
No plain-language summary yet for this grant — the official description below is the best source.
What it funds
Official description from grants.gov
This Notice of Funding Opportunity (NOFO) invites applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscripts. This NOFO uses a cooperative agreement mechanism (U01) and runs in parallel with a companion NOFO (RFA-DK-27-136).
Who can apply
- City or township governments
- County governments
- For-profit organizations other than small businesses
- Independent school districts
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Others
- Private institutions of higher education
- Public and State controlled institutions of higher education
- Public housing authorities / Indian housing authorities
- Small businesses
- Special district governments
- State governments
Program history
USASpending.govAssistance listing 93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research
Real awards this federal program has made — the whole assistance listing (93.847), not just this notice.
| Fiscal year | Awards | Median award | Middle half |
|---|---|---|---|
| FY 2026 (so far) | 616 | $537,141 | $153,319 – $771,172 |
| FY 2025 | 659 | $730,832 | $270,038 – $1,572,806 |
| FY 2024 | 929 | — | — |
| FY 2023 | 961 | — | — |
| FY 2022 | 975 | — | — |
| FY 2021 | 1,012 | — | — |
For comparison, this notice advertises Up to $1,000,000.
Dollar figures are based on the 1,000 most recent awards we store, not all 5,152 — award counts are complete.
- BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE $6,282,406 · FY 2026
- THE LELAND STANFORD JUNIOR UNIVERSITY $5,583,712 · FY 2026
- RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA $5,180,852 · FY 2026
- NORTHWESTERN UNIVERSITY $4,764,127 · FY 2025
- UNIVERSITY OF SOUTH FLORIDA $4,640,761 · FY 2026
Source: USASpending.gov · refreshed Aug 23, 2026